Blueprint Medicines Corporation Stock News

CAMBRIDGE, Mass. and SAN DIEGO, Nov. 29, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the company has entered into a definitive agreement under which it will acquire Lengo Therapeutics, a privately held precision oncology company, for $250

Blueprint Medicines Corporation (NASDAQ: BPMC) has agreed to acquire Lengo Therapeutics, a privately held precision oncology company. The deal consideration includes $250 million in cash plus $215

Invesco Ltd. lessened its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 88.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 160,332 shares of the biotechnology companys stock after selling 1,202,402 shares during the quarter. Invesco Ltd. owned approximately 0.27% of Blueprint Medicines []

The European Commission approves Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumor.

Roche (RHHBY) wins EC approval for Gavreto for the treatment of adults with RET fusion-positive advanced NSCLC.

Blueprint Medicines Co. (NASDAQ:BPMC) CEO Jeffrey W. Albers sold 30,000 shares of the stock in a transaction that occurred on Monday, November 15th. The stock was sold at an average price of $114.50, for a total value of $3,435,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is []

Shares of Blueprint Medicines Co. (NASDAQ:BPMC) have received an average rating of Buy from the thirteen research firms that are presently covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. []

Shares of Blueprint Medicines Co. (NASDAQ:BPMC) have received a consensus recommendation of Buy from the thirteen analysts that are currently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 []

Bank of America Corp DE increased its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 7.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 258,557 shares of the biotechnology companys stock after purchasing an additional 17,278 shares during the quarter. []

Bank of America Corp DE increased its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 7.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 258,557 shares of the biotechnology companys stock after purchasing an additional 17,278 shares during the quarter. Bank []

Related Stocks: KNTE , CNTA , TYRA , TNGX , BPMC , FULC , TPTX , IOVA , SGEN , AMRN , RACA , KDMN , AGEN , BMRN ,

Blueprint Medicines (NASDAQ:BPMC) had its target price upped by Raymond James from $122.00 to $133.00 in a research report report published on Wednesday, PriceTargets.com reports. They currently have a strong-buy rating on the biotechnology companys stock. Several other brokerages have also recently issued reports on BPMC. TheStreet cut shares of Blueprint Medicines from a c []

Blueprint Medicines Corporation's (BPMC) CEO Jeff Albers on Q3 2021 Results - Earnings Call Transcript

CAMBRIDGE, Mass., Oct. 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunothera

CAMBRIDGE, Mass., Sept. 3, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunothera